ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019
dc.contributor.author | Balmaceda, Nicole | |
dc.contributor.author | Aziz, Muhammad | |
dc.contributor.author | Chandrasekar, Viveksandeep Thoguluva | |
dc.contributor.author | McClune, Brian | |
dc.contributor.author | Kambhampati, Suman | |
dc.contributor.author | Shune, Leyla | |
dc.contributor.author | Abdallah, Al-Ola | |
dc.contributor.author | Anwer, Faiz | |
dc.contributor.author | Majeed, Aneela | |
dc.contributor.author | Qazilbash, Muzaffar | |
dc.contributor.author | Ganguly, Siddhartha | |
dc.contributor.author | McGuirk, Joseph | |
dc.contributor.author | Mohyuddin, Ghulam Rehman | |
dc.date.accessioned | 2021-06-28T16:00:37Z | |
dc.date.available | 2021-06-28T16:00:37Z | |
dc.date.issued | 2021-06-26 | |
dc.identifier.citation | Balmaceda, N., Aziz, M., Chandrasekar, V.T. et al. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21, 730 (2021). https://doi.org/10.1186/s12885-021-08451-x | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/31711 | |
dc.description | A grant from the One-University Open Access Fund at the University of Kansas was used to defray the author's publication fees in this Open Access journal. The Open Access Fund, administered by librarians from the KU, KU Law, and KUMC libraries, is made possible by contributions from the offices of KU Provost, KU Vice Chancellor for Research & Graduate Studies, and KUMC Vice Chancellor for Research. For more information about the Open Access Fund, please see http://library.kumc.edu/authors-fund.xml. | en_US |
dc.description.abstract | Background Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments.Methods We performed a systematic review to evaluate the monthly risk of grade III/IV infection, pneumonia, and neutropenia in patients with myeloma enrolled in randomized clinical trials (RCTs).Results The risk of grade III or higher infection, pneumonia, and neutropenia persists among all phases of treatment. There was no statistical difference in grade III or higher infection, pneumonia, and neutropenia between frontline and relapsed/refractory setting. In the maintenance setting, the complications of infection, pneumonia, and neutropenia were low, but not negligible. Three-drug regimens were no more likely than two-drug regimens to have an increased risk of Grade III or higher infection.Conclusions This is the first study to quantify the monthly risk of grade III or higher infection, pneumonia, and neutropenia across different treatment regimens in the frontline, maintenance, and relapsed/refractory settings. The results of our systematic review demonstrate a significant risk for severe infection, pneumonia, and neutropenia in patients with MM. Further studies are needed to determine the value of antibiotic prophylaxis in a broader myeloma patient population, as well as other approaches that will further mitigate the morbidity and mortality related to infection in this vulnerable patient population. | en_US |
dc.publisher | BMC | en_US |
dc.rights | © The Author(s). 2021. This work is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Multiple myeloma | en_US |
dc.subject | Proteasome inhibitors | en_US |
dc.subject | Anti-CD38 | en_US |
dc.subject | Cytotoxic therapy | en_US |
dc.subject | Infection | en_US |
dc.title | Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019 | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Balmaceda, Nicole | |
kusw.kuauthor | Shune, Leyla | |
kusw.kuauthor | Abdallah, Al-Ola | |
kusw.kuauthor | Ganguly, Siddhartha | |
kusw.kuauthor | McGuirk, Joseph | |
kusw.kuauthor | Mohyuddin, Ghulam Rehman | |
kusw.kudepartment | KU Medical Center | en_US |
dc.identifier.doi | 10.1186/s12885-021-08451-x | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
-
KU Scholarly Papers Funded by the KU Open Access Fund [212]
-
University of Kansas Medical Center Scholarly Works [77]
KUMC faculty publications from BioMed Central